Profil Institute was developed at the heart of diabetes research with its founding scientists hailing from a number of academic centers, amongst them the World Health Organization Collaborating Center of Diabetes at Heinrich-Heine University of Düsseldorf and Harvard University. Profil Institute has been involved with every clinically promising drug class and device development in diabetes and in more than 200 clinical studies since the company’s inception in 2004.
Although considered a CRO (Clinical Research Organization), the founders of Profil Institute have never considered their company to accurately fit that description. Instead they coined the term CRI, Clinical Research Institute, and define it as “uniting independent academic science with the professionalism of the pharmaceutical industry” – combining distinct academic intellect with the means to effectively design and execute clinical trials for their biopharmaceutical clients. In essence, Profil Institute’s “deeper value” CRI approach is based on assisting their clients in the design and execution of the most meaningful early phase clinical studies, thereby generating relevant high quality data and accelerating the drug and device development process.
In Profil Institute’s case, “specialized”, can be added in front of the term CRI because of their disease focus on diabetes, obesity and cardiometabolic diseases. This concept of a specialized clinical research institute gives Profil Institute a substantial advantage in the industry by enabling Profil Institute to outperform peers in meaningful study design, study execution and study data interpretation.
Profil Institute is an experienced science and quality driven partner for the execution of early phase clinical trials, uniquely positioned to design, analyze, interpret, present and publish diabetes, obesity and cardiometabolic studies.
More than 300 original articles and reviews, primarily published in highly ranked international journals highlight Profil Institute’s scientific expertise.